This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Combita, A.-L.
Right arrow Articles by Coursaget, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Combita, A.-L.
Right arrow Articles by Coursaget, P.

 Previous Article  |  Next Article 

Journal of Virology, July 2002, p. 6480-6486, Vol. 76, No. 13
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.13.6480-6486.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses

Alba-Lucia Combita,1 Antoine Touzé,1 Latifa Bousarghin,1 Neil D. Christensen,2 and Pierre Coursaget1*

Laboratoire de Virologie Moléculaire, INSERM EMIU 00-10 and USC INRA, Faculté des Sciences Pharmaceutiques, 37200 Tours, France,1 The Jake Gittlen Cancer Research Institute, Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania 170332

Received 15 November 2001/ Accepted 28 March 2002

The neutralizing activities of polyclonal antibodies and monoclonal antibodies (MAbs) obtained by immunization of mice with L1 virus-like particles (VLPs) were investigated by using pseudovirion infectivity assays for human papillomavirus type 16 (HPV-16), HPV-31, HPV-33, HPV-45, HPV-58, and HPV-59 to obtain a better definition of cross-neutralization between high-risk HPVs. In this study, we confirmed and extended previous studies indicating that most genital HPV genotypes represent separate serotypes, and the results suggest that the classification of serotypes is similar to that of genotypes. In addition, three cross-neutralizing MAbs were identified (HPV-16.J4, HPV-16.I23, and HPV-33.E12). MAb HPV-16.J4 recognized a conserved linear epitope located within the FG loop of the L1 protein, and HPV-16.I23 recognized another located within the DE loop. The results suggested that reactivity of MAb HPV-16.I23 to L1 protein is lost when leucine 152 of the HPV-16 L1 protein is replaced by phenylalanine. This confirmed the existence of linear epitopes within the L1 protein that induce neutralizing antibodies, and this is the first evidence that such linear epitopes induce cross-neutralization. However, the cross-neutralization induced by L1 VLPs represents less than 1% of the neutralizing activity induced by the dominant conformational epitopes, and it is questionable whether this is sufficient to offer cross-protection in vivo.

* Corresponding author. Mailing address: Laboratoire de Virologie Moléculaire, Faculté des Sciences Pharmaceutiques "Philippe Maupas," 31 Avenue Monge, 37200 Tours, France. Phone: 33 2 47 36 72 56 or 33 2 47 36 71 90. Fax: 33 2 47 36 71 88. E-mail: coursaget{at}univ-tours.fr.

Journal of Virology, July 2002, p. 6480-6486, Vol. 76, No. 13
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.13.6480-6486.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rizk, R. Z., Christensen, N. D., Michael, K. M., Muller, M., Sehr, P., Waterboer, T., Pawlita, M. (2008). Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J. Gen. Virol. 89: 117-129 [Abstract] [Full Text]  
  • Xu, Y., Wang, Q., Han, Y., Song, G., Xu, X. (2007). Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56: 907-913 [Abstract] [Full Text]  
  • Poland, G. A., Jacobson, R. M., Koutsky, L. A., Tamms, G. M., Railkar, R., Smith, J. F., Bryan, J. T., Cavanaugh, P. F. Jr, Jansen, K. U., Barr, E. (2005). Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial. Mayo Clin Proc. 80: 601-610 [Abstract]  
  • Barth, H., Schafer, C., Adah, M. I., Zhang, F., Linhardt, R. J., Toyoda, H., Kinoshita-Toyoda, A., Toida, T., van Kuppevelt, T. H., Depla, E., von Weizsacker, F., Blum, H. E., Baumert, T. F. (2003). Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate. J. Biol. Chem. 278: 41003-41012 [Abstract] [Full Text]  
  • Varsani, A., Williamson, A.-L., de Villiers, D., Becker, I., Christensen, N. D., Rybicki, E. P. (2003). Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16. J. Virol. 77: 8386-8393 [Abstract] [Full Text]  
  • Bousarghin, L., Touze, A., Sizaret, P.-Y., Coursaget, P. (2003). Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter Cells. J. Virol. 77: 3846-3850 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»